Evidence map›Paper›PMID 41288499›Full record

ArticleDiabetes2026

B Lymphocytes Impede Tregs to Erode Islet Tolerance in Type 1 Diabetes.

Christopher S Wilson, Blair T Stocks, Alexander C Falk, Daniel J Moore

Abstract read
In one paragraph

Article in Diabetes, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Christopher S WilsonIan Burr Division of Endocrinology and Diabetes, Department of Pediatrics, Vanderbilt University Medical Center, Nashville, TN.
Blair T StocksDivision of Male Reproductive Medicine Surgery, Scott Department of Urology, Baylor College of Medicine, Houston, TX.
Alexander C FalkIan Burr Division of Endocrinology and Diabetes, Department of Pediatrics, Vanderbilt University Medical Center, Nashville, TN.
Daniel J MooreIan Burr Division of Endocrinology and Diabetes, Department of Pediatrics, Vanderbilt University Medical Center, Nashville, TN.ORCID 0000-0002-6889-9345

Funding

Tumor Immunology and Microenvironment Research ProgramP30CA068485 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Ben Ho Park · 1995 to 2026
$172.8M
Translational Analysis CoreP30DK058404 · NIDDK · VANDERBILT UNIVERSITY MEDICAL CENTER · PI MARY Kay WASHINGTON · 2002 to 2026
$29.9M
Disruption of Treg-dependent Tolerance by B lymphocytes in Islet TransplantationR56DK128337 · NIDDK · VANDERBILT UNIVERSITY MEDICAL CENTER · PI MOORE, DANIEL J. · 2021 to 2021
$173k
Targeting B lymphocyte Signaling to Reprogram Autoimmunity in Type 1 DiabetesF31DK107321 · NIDDK · VANDERBILT UNIVERSITY · PI WILSON, CHRISTOPHER S. · 2015 to 2017
$84k
Beatson Family Foundation 2019-016Breakthrough T1D 3-PDF-2023-1320-A-NJP Fletcher Family FoundationJuvenile Diabetes Research Foundation International 5-CDA-2014-209-A-NNCI NIH HHS P30 CA068485NIDDK NIH HHS F31 DK107321NIDDK NIH HHS P30 DK058404NIDDK NIH HHS R56 DK128337NIH HHS 1F31DK107321NIH HHS 1R56DK128337NIH HHS DK058404NIH HHS P30 CA68485
6 · The paper itself

Abstract

B lymphocytes are thought to drive β-cell destruction in type 1 diabetes (T1D) by activating anti-islet T cells. However, the observation that autoreactive T-cell activation and disease progression can occur without B cells challenges this view. Still, preclinical and clinical studies have shown that B-cell depletion alleviates β-cell destruction, suggesting a critical role for B cells in T1D. Our findings propose an alternative function for B cells, impairing regulatory T cells (Tregs) that would otherwise protect islets. In the NOD islet transplant model, we show that B-cell absence enables transplant tolerance, allowing Tregs to become responsive to immune therapy and confer allograft protection. Extending this to spontaneous diabetes, we have found that insulin-reactive Tregs are reduced in NOD mice in proportion to insulin-reactive B cells, while effector T cells remain unaffected. Moreover, Tregs from B-cell–deficient NOD mice better restrained β-cell destruction than those from B-cell–sufficient environments. Together, these findings indicate that autoreactive B cells primarily erode immune regulation by culling islet-protective Tregs. Thus, therapies that mobilize Tregs could be more effective when combined with B-cell–targeting strategies in islet transplant or T1D prevention. ARTICLE HIGHLIGHTS: This study expands the role of B lymphocytes in type 1 diabetes by demonstrating how B cells influence the development and function of regulatory T cells (Tregs) during islet transplant and autoimmune progression. This study was done to explain how B lymphocytes regulate the progression of anti-islet immunity, even when they appear dispensable for effector cell activation. B-cell deficiency (using NOD.μMT mice) enables durable islet transplant tolerance, enhances the expansion of Helios+ Tregs, increases the ratio of insulin-reactive Tregs to effector T cells, and enhances islet-protective Treg function. These findings indicate that B lymphocytes accelerate destructive immunity by negatively regulating Treg development and function. Targeting the harmful B-cell-Treg interactions, particularly in the thymic environment, may offer new, more selective therapeutic strategies to prevent anti-islet immunity.

Indexed as

B-LymphocytesDiabetes Mellitus, Type 1Immune ToleranceIslets of LangerhansIslets of Langerhans TransplantationT-Lymphocytes, RegulatoryAnimalsMiceMice, Inbred NOD

Identifiers

PMID41288499
PMCPMC12823342

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.